StockStory favors Watts Water (WTS), flags West Pharma (WST) and MarketAxess (MKTX) as higher-risk cash plays

StockStory said May 15, 2026, that Watts Water Technologies (NYSE: WTS) remains on its buy list, while West Pharmaceutical Services (NYSE: WST) and MarketAxess (NASDAQ: MKTX) carry higher risk despite cash-related balance-sheet metrics. Watts Water had a net cash position of $176.9 million, equal to 1.8% of market value, and traded at $297.50, or 24.5 times forward earnings. West Pharmaceutical held $205.2 million in net cash, equal to 0.9% of market value, but traded at $320, or 37.4 times forward earnings. MarketAxess reported a net cash position of negative $103.6 million, equal to negative 2% of market value, and traded at $145.26, or 18.1 times forward earnings. StockStory cited concerns including revenue stagnation, market-share pressure and limited scalability among cash-heavy companies, while noting that a strong cash position does not necessarily indicate attractive growth prospects.